Table 2: Treatment results of childhood B-cell NHL in different working groups.

Study	Country	No patients	Time period	Protocol	EFS	OS
Wessels et al. [7]	S. Africa	63	1983-2002	COMP, LMB-89,96	25-87%
Reiter et al. [2]	Germany	111	1986-1990	BFM-86		81%
Burkhardt et al. [8]	International	1004	1986-2002	BFM-86, 90, 95	87%
Patte et al. [4]	France	420	1989-1996	LMB-89	92%
Müller et al. [9]	Hungary	108	1990-2004	BFM-90, 95	81%	83%
Cairo et al. [10]	USA	46	1991-1995	Orange, CCG-5911	80%
Kavan et al. [11]	Czech Republic	82	1991-1997	BFM-90	74%	80%
Pillon et al. [12]	Italy	105	1992-1997	AIEOP-LNH 92	87.5%
Chantada et al. [13]	Argentina	57	1994-1999	BFM-90	79%	81%
Marky et al. [14]	Nordic countries	121	1995-2000	NOPHONHL-95	91%	91%
Celkan et al. [15]	Turkey	48	1995-2007	BFM-95	76.6%	78.1%
Patte et al. [4]	France	397	1996-2001	LMB-96	93.3%
Dokmanovic et al. [16]	Serbia	57	1997-2011	BFM-95	84.1%	93%
Eldar et al. [17]	Israel	88	2000-2005	LMB-96	88.6%	90.9%
Tsurusawa et al. [18]	Japan	321	2001-2012	B-NHL03	87.4%	92.7%
Sun et al. [19]	China	138	1998-2011	Modified BFM-90	85.8%	85.8%
Nelson et al. [20]	USA	90	1996-2001	CCG-5961		89%